Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Sep 30;9(9):CD009883.
doi: 10.1002/14651858.CD009883.pub2.

Thrombopoietin mimetics for patients with myelodysplastic syndromes

Helga Dodillet  1 , Karl-Anton Kreuzer, Ina Monsef, Nicole Skoetz
Affiliations
Meta-Analysis

Thrombopoietin mimetics for patients with myelodysplastic syndromes

Helga Dodillet et al. Cochrane Database Syst Rev. .

Abstract

Background: Myelodysplastic syndrome (MDS) is one of the most frequent haematologic malignancies of the elderly population and characterised by progenitor cell dysplasia with ineffective haematopoiesis and a high rate of transformation to acute myeloid leukaemia (AML). Thrombocytopenia represents a common problem for patients with MDS. ranging from mild to serious bleeding events and death. To manage thrombocytopenia, the current standard treatment includes platelet transfusion, unfortunately leading to a range of side effects. Thrombopoietin (TPO) mimetics represent an alternative treatment option for MDS patients with thrombocytopenia. However, it remains unclear, whether TPO mimetics influence the increase of blast cells and therefore to premature progression to AML.

Objectives: To evaluate the efficacy and safety of thrombopoietin (TPO) mimetics for patients with MDS.

Search methods: We searched for randomised controlled trials in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 2000 to August 2017), trials registries (ISRCTN, EU clinical trials register and clinicaltrials.gov) and conference proceedings. We did not apply any language restrictions. Two review authors independently screened search results, disagreements were solved by discussion.

Selection criteria: We included randomised controlled trials comparing TPO mimetics with placebo, no further treatment or another TPO mimetic in patients with MDS of all risk groups, without gender, age or ethnicity restrictions. Additional chemotherapeutic treatment had to be equal in both arms.

Data collection and analysis: Two review authors independently extracted data and assessed the quality of trials, disagreements were resolved by discussion. Risk ratio (RR) was used to analyse mortality during study, transformation to AML, incidence of bleeding events, transfusion requirement, all adverse events, adverse events >= grade 3, serious adverse events and platelet response. Overall survival (OS) and progression-free survival (PFS) have been extracted as hazard ratios, but could not be pooled as results were reported in heterogenous ways. Health-related quality of life and duration of thrombocytopenia would have been analysed as standardised mean differences, but no trial reported these outcomes.

Main results: We did not identify any trial comparing one TPO mimetic versus another. We analysed six eligible trials involving 746 adult patients. All trials were reported as randomised and double-blind trials including male and female patients. Two trials compared TPO mimetics (romiplostim or eltrombopag) with placebo, one trial evaluated eltrombopag in addition to the hypomethylating agent azacitidine, two trials analysed romiplostim additionally to a hypomethylating agent (azacitidine or decitabine) and one trial evaluated romiplostim in addition to the immunomodulatory drug lenalidomide. There are more data on romiplostim (four included, completed, full-text trials) than on eltrombopag (two trials included: one full-text publication, one abstract publication). Due to small sample sizes and imbalances in baseline characteristics in three trials and premature termination of two studies, we judged the potential risk of bias of all included trials as high.Due to heterogenous reporting, we were not able to pool data for OS. Instead of that, we analysed mortality during study. There is little or no evidence for a difference in mortality during study for thrombopoietin mimetics compared to placebo (RR 0.97, 95% confidence interval (CI) 0.73 to 1.27, N = 6 trials, 746 patients, low-quality evidence). It is unclear whether the use of TPO mimetics induces an acceleration of transformation to AML (RR 1.02, 95% CI 0.59 to 1.77, N = 5 trials, 372 patients, very low-quality evidence).Thrombopoietin mimetics probably improve the incidence of all bleeding events (RR 0.92, 95% CI 0.86 to 0.99, N = 5 trials, 390 patients, moderate-quality evidence). This means that in the study population, 713 out of 1000 in the placebo arm will have a bleeding event, compared to 656 of 1000 (95% CI 613 to 699) in the TPO mimetics arm. There is little or no evidence for a difference that TPO mimetics significantly diminish the rate of transfusion requirement (RR 0.83, 95% CI 0.66 to 1.05, N = 4 trials, 358 patients, low-quality evidence). No studies were found that looked at quality of life or duration of thrombocytopenia.There is no evidence that patients given TPO mimetics suffer more all adverse events (RR 1.01, 95% CI 0.96 to 1.07, N = 5 trials, 390 patients, moderate-quality evidence). There is uncertainty whether the number of serious adverse events decrease under therapy with TPO mimetics (RR 0.89, 95% CI 0.54 to 1.46, N = 4 trials, 356 patients, very low-quality evidence).We identified one ongoing study and one study marked as completed (March 2015), but without publication of results for MDS patients (only results reported for AML and MDS patients together). Both studies evaluate MDS patients receiving eltrombopag in comparison to placebo.

Authors' conclusions: No trial evaluated one TPO mimetic versus another.Six trials including adult patients analysed one TPO mimetic versus placebo, sometimes combined with standard therapy in both arms. Given the uncertainty of the quality of evidence, meta-analyses show that there is little or no evidence for a difference in mortality during study and premature progress to AML. However, these assumptions have to be further explored. Treatment with TPO mimetics resulted in a lower number of MDS patients suffering from bleeding events.There is no evidence for a difference between study groups regarding transfusion requirement. Enlarged sample sizes and a longer follow-up of future trials should improve the estimate of safety and efficacy of TPO mimetics, moreover health-related quality of life should be evaluated. As two ongoing studies currently investigate eltrombopag (one already completed, but without published results), we are awaiting results for this drug.

PubMed Disclaimer

Conflict of interest statement

Helga Dodillet: none known

Nicole Skoetz: none known

Ina Monsef: none known

Karl‐Anton Kreuzer: none known

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.1 Mortality during study ‐ all.
5
5
Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.7 Transformation to AML ‐ all.
6
6
Forest plot of comparison: 1 Thrombopoietin mimetics versus placebo, outcome: 1.12 Incidence of bleeding events ‐ all.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Dickinson 2016 {published data only}
    1. Dickinson MJ, Cherif H, Fenaux P, Mittleman M, Verma A, Socorro M, et al. Thrombopoietin (TPO) receptor agonist eltrombopag in combination with azacitidine (AZA) for primary treatment of myelodysplastic syndromes (MDS) patients with thrombocytopenia: Outcomes from the randomized, placebo‐controlled, phase III support study. Blood. 2016.
Giagounidis 2014 {published data only}
    1. Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, et al. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low / intermediate‐1‐risk myelodysplastic syndrome and thrombocytopenia. Cancer 2014;120(12):1838‐46. - PMC - PubMed
    1. Giagounidis A, Mufti GJ, Kantarjian HM, Fenaux P, Sekeres MA, Szer J, et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndromes (MDS): Results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2011.
    1. Kantarjian H, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, et al. Romiplostim in thrombocytopenic patients with low‐ or int‐1‐risk‐MDS results in reduced bleeding without impacting leukemic progression: Final follow‐up results from a randomized, double‐blind, placebo‐controlled study. Blood. 2016.
    1. Kantarjian HM, Mufti G, Fenaux P, Sekeres M, Szer J, Platzbecker U, et al. Treatment with romiplostim, a thrombopoietin‐receptor agonist, in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Updated follow‐up results for acute myeloid leukaemia (AML) and survival from a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2014; Vol. 124 (21):1553.
    1. Kantarjian HM, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study. Blood. 2012.
Greenberg 2013 {published data only}
    1. Greenberg PL, Garcia‐Manero G, Moore M, Damon L, Roboz G, Hu K, et al. A randomized controlled trial of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving decitabine. Leukemia & Lymphoma 2013;54(2):321‐8. - PubMed
    1. Greenberg PL, Garcia‐Manero G, Moore MR, Damon LE, Roboz GJ, Wei H, et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood 2009;114:Abstract: 1769.
Kantarjian 2010 {published data only}
    1. Kantarjian H, Giles F, Greenberg P, Paquette R, Wang E, Gabrilove J, et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood. 2008; Vol. 112:224. - PMC - PubMed
    1. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;116(17):3163‐70. - PMC - PubMed
Platzbecker 2015 {published data only}
    1. Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, et al. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo‐controlled, double‐blind, phase 1/2 trial. Lancet Haematology 2015;2(10):e417‐26. [PUBMED: 26686043] - PubMed
    1. Platzbecker U, Wong RSM, Araujo S, Feigert J, Bennett J, Messam C, et al. Randomized, placebo (PBO)‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag (EPAG) in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS). Haematologica. 2015.
    1. Platzbecker U, Wong RSM, Verma A, Abboud CN, Araujo S, Chiou TJ, et al. Randomized, placebo‐controlled, phase I/II trial of the thrombopoietin receptor agonist eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes or acute myloid leukaemia‐ a subgroup analysis of patients receiving concomitant anticancer therapy. Blood. 2013; Vol. 122 (21).
    1. Wroblewski S, Shi W, Mudd P, Aivado M. Eltrombopag in thrombocytopenic patients with advanced myelodysplastic syndromes (MDS) or secondary acute myeloid leukaemia after MDS: A phase I/II study. Journal of Clinical Oncology. 2010; Vol. 28, issue 15.
Wang 2012 {published data only}
    1. Lyons RM, Larson RA, Kosmo MA, Gandhi SL, Delong CM, Dreisbach L, et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. 2009; Vol. 114:1770.
    1. Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, et al. A randomized, double‐blind, placebo‐controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate‐1 risk myelodysplastic syndrome receiving lenalidomide. Journal of Hematology & Oncology 2012;5:71. - PMC - PubMed

References to studies excluded from this review

Fenaux 2011 {published data only}
    1. Fenaux P, Kantarjian HM, Muus P, Lyons RM, Larson RA, Sekeres MA, et al. Update of an open‐label extension study evaluating the long‐term safety and efficacy of romiplostim in thrombocytopenic patients with myelodysplastic syndromes (MDS). Blood 2011;118:Abstract: 2772.
    1. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology 2010;28(3):437‐44. - PubMed
    1. Sekeres M, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci‐Bresler A, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with myelodysplastic syndrome (MDS). Journal of Clinical Oncology 2009;27((suppl; Abstract 7009)):15s. - PubMed
Mavroudi 2011 {published data only}
    1. Mavroudi I, Pyrovolaki K, Pavlaki K, Kozana A, Psyllaki M, Kalpadakis C, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leukemia Research 2011;35(3):323‐8. - PubMed
Mittelman 2016 {published data only}
    1. Mittelman M, Platzbecker U, Afanasyev B, Grosicki S, Wong RSM, Anagnostopoulos A, et al. Thrombopoietin receptor agonist eltrombopag for advanced MDS or AML and severe thrombocytopenia: 12‐week, randomized, placebo‐controlled, phase 2 aspire study. EHA 2016. June 2016.
Perez Ruixo 2013 {published data only}
    1. Perez Ruixo JJ, Doshi S, Wang YM, Mould DR. Romiplostim dose–response in patients with myelodysplastic syndromes. British Journal of Clinical Pharmacology 2013;75(6):1445‐54. - PMC - PubMed
Rice 2006 {published data only}
    1. Rice L. Drug evaluation: AMG‐531 for the treatment of thrombocytopenias. Current Opinion in Investigational Drugs 2006;7(9):834‐41. - PubMed
Sekeres 2011 {published data only}
    1. Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci‐Bresler A, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011;117(5):992‐1000. - PubMed

References to ongoing studies

NCT01440374 {published data only}
    1. A three‐part study of eltrombopag in thrombocytopenic patients with myelodysplastic syndromes or acute myeloid leukaemia (part 1: open‐label, part 2: randomised, double‐blind, part 3: extension). Ongoing study September 2011.
Oliva 2017 {published data only}
    1. Oliva E, Latagliata R, Santini V, Palumbo G, Poloni A, Cortelezzi A, et al. Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and int‐1 risk MDS: Preliminary results of a prospective, randomized, single‐blind placebo‐controlled trial. Haematologica. 2012.
    1. Oliva EN, Alati C, Santini V, Poloni A, Molteni A, Niscola P, et al. Eltrombopag versus placebo for low‐risk myelodysplastic syndromes with thrombocytopenia (EQoL‐MDS): phase 1 results of a single‐blind, randomised, controlled, phase 2 superiority trial. Lancet Haematology 2017;4(3):e127‐36. [PUBMED: 28162984] - PubMed
    1. Oliva EN, Santini V, Zini V, Palumbo GA, Poloni A, Cortelezzi A, et al. Efficacy and safety of eltrombopag for the treatment of thrombocytopenia of low and int‐1 IPSS risk myelodysplastic syndromes: Interim analysis of a prospective, randomized, single‐blind, placebo‐controlled trial (EQoL‐MDS) [abstract no. 923]. Blood. 2012.

Additional references

AMGEN 2011
    1. Harper SE. Important information concerning updates to the US Nplate® (romiplostim). Prescribing Information, 2011. http://www.amgen.com/pdfs/products/NPlate‐DHCP‐2011‐07‐27.pdf.pdf (accessed 10 April 2012).
Bennett 1976
    1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French‐American‐British (FAB) Co‐operative Group. British Journal of Haematology 1976;33:451‐8. - PubMed
Bowen 2003
    1. Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. British Journal of Haematology 2003;120(2):187‐200. - PubMed
Case 2000
    1. Case BC, Hauck ML, Yeager RL, Simkins AH, Serres M, Schmith VD, et al. The pharmacokinetics and pharmacodynamics of GW395058, a peptide agonist of the thrombopoietin receptor, in the dog, a large‐animal model of chemotherapy‐induced thrombocytopenia. Stem Cells (Dayton, Ohio) 2000;18(5):360‐5. [PUBMED: 11007920] - PubMed
Dayyani 2010
    1. Dayyani F, Conley AP, Strom SS, Stevenson W, Cortes JE, Borthakur G, et al. Cause of death in patients with lower‐risk myelodysplastic syndrome. Cancer 2010; Vol. 116, issue 9:2174‐9. - PMC - PubMed
Deeg 2004
    1. Deeg HJ, Jiang PY, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leukemia Research 2004;28:1177‐80. - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Della Porta 2010
    1. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra‐hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2010;96(3):441‐9. - PMC - PubMed
Desborough 2016
    1. Desborough M, Hadjinicolaou AV, Chaimani A, Trivella M, Vyas P, Doree C, et al. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta‐analysis and systematic review. Cochrane Database of Systematic Reviews 2016, Issue 10. [DOI: 10.1002/14651858.CD012055.pub2; PUBMED: 27797129] - DOI - PMC - PubMed
EMEA 2011
    1. European Medicines Agency. Product information: Nplate. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Info... (accessed 10 April 2012).
Fenaux 2009
    1. Fenaux P, Mufti GJ, Hellstrom‐Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher‐risk myelodysplastic syndromes: a randomised, open‐label, phase III study. Lancet Oncology 2009;10(3):223‐32. - PMC - PubMed
Fey 2010
    1. Fey MF, Dreyling M and ESMO Guidelines Working Group. Acute myeloblastic leukaemias and myelodysplastic syndromes in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2010;21 Suppl 5:158‐61. - PubMed
Goldberg 2010
    1. Goldberg S L, Chen E, Corral M, Guo A, Mody‐Patel N, Pecora A L, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Journal of Clinical Oncology 2010;28(17):2847‐52. - PubMed
Gotze 2010
    1. Gotze K, Platzbecker U, Giagounidis A, Haase D, Lubbert M, Aul C, et al. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group. Annals of Hematology 2010;89:841‐50. - PubMed
Greenberg 1997
    1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079‐88. - PubMed
Greenberg 2009
    1. Greenberg PL, Garcia‐Manero G, Moore MR, Damon LE, Roboz GJ, Wei H, et al. Efficacy and safety of romiplostim in patients with low or intermediate‐risk myelodysplastic syndrome (MDS) receiving decitabine. Blood. Washington (DC): American Society of Hematology, 2009:1769.
Greenberg 2011
    1. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, et al. Myelodysplastic syndrome. NCCN Clinical Practice Guidelines in Oncology. V.2.2011. http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf. - PMC - PubMed
Harris 1999
    1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller‐Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting‐Airlie House, Virginia. Journal of Clinical Oncology 1999;17:3835‐49. - PubMed
Higgins 2011a
    1. Higgins JPT, Deeks JJ, Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011b
    1. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011c
    1. Higgins JPT, Altman DG, Sterne JAC (editors) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org 2011.
Ikeda 2009
    1. Ikeda Y, Miyakawa Y. Development of thrombopoietin receptor agonists for clinical use. Journal of Thrombosis and Haemostasis 2009;7(Suppl 1):239‐44. - PubMed
Jenkins 2007
    1. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109(11):4739‐41. - PubMed
Kantarjian 2006
    1. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; Vol. 106, issue 8:1794‐803. - PubMed
Kantarjian 2007
    1. Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007;109:1705‐14. - PubMed
Kantarjian 2009
    1. Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, et al. Safety and efficacy of romiplostim in patients with lower‐risk myelodysplastic syndrome and thrombocytopenia. Journal of Clinical Oncology 2009;28(3):437‐44. - PubMed
Kantarjian 2010a
    1. Kantarjian HM, Giles FJ, Greenberg PL, Paquette RL, Wang ES, Gabrilove JL, et al. Phase 2 study of romiplostim in patients with low‐ or intermediate‐risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010;116(17):3163‐70. - PMC - PubMed
Kaushansky 2006
    1. Kaushansky K. Lineage‐specific hematopoietic growth factors. New England Journal of Medicine 2006;354:2034‐45. - PubMed
Kuter 2007
    1. Kuter DJ. New thrombopoietic growth factors. Blood 2007;109(11):4607‐16. - PMC - PubMed
Kuter 2009
    1. Kuter DJ. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annual Review of Medicine 2009;60:193‐206. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J (authors) on behalf of the Cochrane Information Retrieval Methods Group. Chapter 6: Searching for studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
List 2006a
    1. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine 2006;355:1456‐65. - PubMed
Lyons 2009
    1. Lyons RM, Larson RA, Kosmo MA, Gandhi S, Liu D, Chernoff M, et al. Randomized phase II study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate risk myelodysplastic syndrome (MDS) receiving lenalidomide. Blood. Washington (DC): American Society of Hematology, 2009:1770.
McCullough 2000
    1. McCullough J. Current issues with platelet transfusion in patients with cancer. Seminars in Hematology 2000;37:3‐10. - PubMed
Melchert 2008
    1. Melchert M, List A. Targeted therapies in myelodysplastic syndrome. Seminars in Hematology 2008;45(1):31‐8. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006‐12. - PubMed
Neukirchen 2009
    1. Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, et al. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. European Journal of Haematology 2009;83(5):477‐82. - PubMed
Nimer 2008
    1. Nimer SD. Myelodysplastic syndromes. Blood 2008;111(10):4841‐51. - PubMed
O'Connor 2011
    1. O'Connor D, Green S, Higgins JPT (editors). Chapter 5: Defining the review question and developing criteria for including studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ..
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
Prica 2014
    1. Prica A, Sholzberg M, Buckstein R. Safety and efficacy of thrombopoietin‐receptor agonsits in myelodysplastic syndromes: a systematic review and meta‐analysis of randomized controlled trials. British Journal of Haematology 2014;167:626‐38. - PubMed
Rebulla 2005
    1. Rebulla P. A mini‐review on platelet refractoriness. Haematologica 2005;90:247‐53. - PubMed
Santini 2010
    1. Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Maio M, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leukemia Research 2010;34:1576‐88. - PubMed
Sekeres 2011a
    1. Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci‐Bresler A, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011;117(5):992‐1000. - PubMed
Sekeres 2011b
    1. Sekeres MA. Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. Journal of the National Comprehensive Cancer Network 2011;9:57‐63. - PubMed
Sloand 2005
    1. Sloand EM, Greenberg P, Wu C, Young NS, Barrett J. Immunosuppressive treatment is associated with durable responses and a survival advantage in younger patients with int‐1 myelodysplastic syndrome. Blood 2005;106:2519.
Stasi 2010
    1. Stasi R, Bosworth J, Rhodes E, Shannon MS, Willis F, Gordon‐Smith EC. Thrombopoietic agents. Blood 2010;24(4‐5):179‐90. - PubMed
Sterne 2011
    1. Sterne JAC, Egger M, Moher D (editors) on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. - PMC - PubMed
Vardiman 2009
    1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937‐51. - PubMed
Wang 2004
    1. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clinical Pharmacology and Therapeutics 2004;76(6):628‐38. - PubMed
Will 2009
    1. Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson‐Miller C L, et al. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009;114(18):3899‐908. - PMC - PubMed
Zeng 2011
    1. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD008235] - DOI - PMC - PubMed

References to other published versions of this review

Dodillet 2012
    1. Dodillet H, Skoetz N, Kreuzer KA, Monsef I, Engert A, Bauer K. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD009883] - DOI - PMC - PubMed
Kantarjian 2012
    1. Kantarjian HM, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, et al. Treatment with the thrombopoietin (TPO)‐ receptor agonist romiplostim in thrombocytopenic patients (pts) with low or intermediate‐1 (int‐1) risk myelodysplastic syndrome (MDS): Follow‐up AML and survival results of a randomized, double‐blind, placebo (PBO)‐ controlled study [abstract no. 421]. Blood. 2012.

Publication types

MeSH terms